24
Participants
Start Date
January 15, 2018
Primary Completion Date
December 18, 2021
Study Completion Date
December 18, 2021
Sequential Packaging (SET)
"Sequential chemotherapy:~* Thiotepa 5 mg / kg / day for 1 day (D-13)~* Cyclophosphamide 400 mg / m² / day for 4 days (J-12 to J-9)~* Etoposide 100 mg / m² / day for 4 days (J-12 to J-9) Repos days J-8 and J-6 Reduced-intensity conditioning (RIC)~* Fludarabine 30 mg / m² / day for 5 days (J-5 to D-1)~* Busulfan IV 3.2 mg / kg / day for 2 days (J-5 and J-4)~* Anti-lymphocyte serum (Thymoglobuline) 2.5 mg / kg / day for 2 days (J-3 and J-2)"
Transfusion graft
Graft of peripheral stem cells is preferred at D0
Prevention of GVHD
"* Cyclophosphamide 50mg / kg / day on days D + 3 and D + 5~* Cyclosporine A (CSA; 3 mg / kg / day IV from D + 6)~* Mycophenolate mofetil (MMF; 30 mg / kg / day, maximum x2 1g / day from day J + 6)"
Care supports
According to the protocols of each center
Lymphocyte injection of prophylactic donor (PDLI)
"According to the protocols of each center. In the absence of clinical indication against-disease (GVHD), phasing MMF between days D + 35 and D + 56, then phasing APF between D + 62 and D + 90~\- PDLI: 3 injections from the D + 120 patients who discontinued immunosuppressive therapy for ≥ 1 month and having no active GVHD or history of acute GVHD grade\> II"
Service d'hématologie Clinique Hôpital Saint Antoine, Paris
Association for Training, Education, and Research in Hematology, Immunology, and Transplantation
OTHER